PAREXEL INTRODUCES CLINICAL RESEARCH TRANSLATION SERVICE
BOSTON, MA, January 11, 2001 — To meet the global need for quality clinical research translations, PAREXEL’s (Nasdaq: PRXL) Scientific and Medical Services Unit (SMS) now offers PAREXEL Translations. This globally available service addresses the need for accurate translations of clinical research activities and data for international clinical trials in compliance with the requirements of regulatory agencies. Leveraging PAREXEL’s global workforce, this service provides translations for a variety of materials spanning the life cycle of a clinical trial, including study start documents, adverse events, study results, clinical trial documents, IND reports, and product labeling. PAREXEL’s translation service, in contrast to conventional commercial translation agencies, utilizes multilingual staff who are expert in clinical trials and clinical data. Clients will have access to high-quality, submission-ready translations which fully meet the needs of sponsors who are submitting results to regulatory agencies.
Julia Cooper, Ph.D., Associate Director of European Medical Writing Services, based in Uxbridge, UK, will oversee the translation service. According to Dr. Cooper, “International trials have become the standard in this industry. By keeping translations in-house, PAREXEL provides accurate, high-quality documents in a timely manner.”
“In addition to expanding our service portfolio, the Translations program illustrates the versatility of our employees to meet the changing needs of our clients,” stated Barbara Dahl, Worldwide Director of Medical Writing Services. “This ingenuity will continue to advance our global effort to provide services that contribute to the efficiency and success of international clinical trials.”
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that accelerate time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. The Company's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 45 locations throughout 29 countries around the world, and has approximately 4,200 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended September 30, 2000, as amended.